A Non Interventional Pilot Study on Machine Learning for ILD detection based on the patient data from digital devices in unresectable stage III Non-Small Cell Lung Cancer Patients receiving durvalumab - iDETECT study

Kouda Shigetaka0 个研究点目标入组 150 人开始时间: 2021年6月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patient who provided written signed informed consent prior to the first study-specific procedures.
•2.Patient who receives durvalumab for unresectable stage III NSCLC at first time following chemoradiation therapy
•3.Patient whose performance status showed 0 or 1 prior to durvalumab treatment
•4.Patient aged 20 age old over
•5.Patient who is able and willing to wear the devices daily for up to 6 months as instructed

•1. Patient under immunotherapy treatment other than durvalumab.
•2. Patient had received prior immunotherapy
•3. Patient under the interventional clinical studies using unapproved drugs or off-label use of drugs
•4. Patient who showed ILD (including radiation pneumonitis) of Grade 2 and higher, after consolidated chemoradiation therapy.
•5.Patient who is judged as not suitable for the study by the study site investigators, in terms of fitting wearable devices, presence of silicone or metallic allergy

发起方

Kouda Shigetaka